Antitrust Antitrust

Advanz exploited lack of rivals to hike drug's price, UK regulator tells judge

By Simon Zekaria
  • 13 Oct 2022 17:45
  • 13 Oct 2022 17:45
Advanz Pharma exploited its power over a thyroid medicine market lacking any competitive pressure by raising the price dramatically, the UK competition watchdog told a judge in London today. 
The Competition and Markets Authority, which fined the drugmaker and two former parent companies last year, rejected the company’s argument that

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Simon Zekaria

Senior Correspondent

Simon Zekaria is a senior correspondent in London, covering UK regulation. Prior to joining MLex, Simon reported on business news for The Wall Street Journal, including on telecommunications, media, technology and consumer affairs. Simon was also a writer for the WSJ on diverse subjects such as Brexit, UK politics and global sport. Simon was previously a correspondent on competition issues and European politics for Thomson Reuters and Agence France-Presse in Brussels. Simon is a graduate of Edinburgh University, with Masters degrees in literature and law. A French speaker, he has studied at the Sorbonne University, Paris.

Discover MLex

Stay on top of global regulatory developments

Latest News